Analysts Set Replimune Group, Inc. (NASDAQ:REPL) Target Price at $9.88

Replimune Group, Inc. (NASDAQ:REPL) has been assigned an average rating of “Hold” from the ten research firms that are currently covering the firm, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the company. The average 1 year price target among analysts that have covered the stock in the last year is $10.00.

REPL has been the topic of several analyst reports. HC Wainwright raised shares of Replimune Group from a “neutral” rating to a “buy” rating and set a $12.00 price target on the stock in a research note on Monday, October 27th. Wedbush lifted their target price on shares of Replimune Group from $18.00 to $19.00 and gave the stock an “outperform” rating in a research note on Wednesday. JPMorgan Chase & Co. upgraded Replimune Group from an “underweight” rating to a “neutral” rating and set a $11.00 price target for the company in a report on Monday, October 20th. Leerink Partners upgraded Replimune Group from a “market perform” rating to an “outperform” rating and raised their price objective for the stock from $3.00 to $13.00 in a report on Monday, October 20th. Finally, Piper Sandler lifted their price objective on Replimune Group from $13.00 to $14.00 and gave the company an “overweight” rating in a research report on Thursday.

Replimune Group Price Performance

Shares of NASDAQ:REPL opened at $7.75 on Thursday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 6.31 and a current ratio of 5.60. The business’s fifty day moving average price is $8.77 and its two-hundred day moving average price is $7.22. The stock has a market cap of $639.92 million, a PE ratio of -2.25 and a beta of 0.73. Replimune Group has a one year low of $2.68 and a one year high of $14.80.

Replimune Group (NASDAQ:REPL) last released its quarterly earnings results on Tuesday, February 3rd. The company reported ($0.77) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.85) by $0.08. On average, analysts forecast that Replimune Group will post -2.97 EPS for the current fiscal year.

Insider Activity at Replimune Group

In other Replimune Group news, Director Kapil Dhingra sold 3,169 shares of the business’s stock in a transaction that occurred on Tuesday, December 9th. The shares were sold at an average price of $10.40, for a total transaction of $32,957.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Konstantinos Xynos sold 7,248 shares of the firm’s stock in a transaction on Monday, November 17th. The shares were sold at an average price of $9.10, for a total transaction of $65,956.80. Following the completion of the transaction, the insider directly owned 139,685 shares in the company, valued at approximately $1,271,133.50. This represents a 4.93% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 25,625 shares of company stock worth $257,607. Company insiders own 5.20% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in REPL. International Assets Investment Management LLC purchased a new stake in shares of Replimune Group in the fourth quarter worth about $29,000. CWM LLC boosted its holdings in Replimune Group by 248.6% in the 4th quarter. CWM LLC now owns 4,047 shares of the company’s stock worth $39,000 after acquiring an additional 2,886 shares during the period. BNP Paribas Financial Markets boosted its holdings in Replimune Group by 37.5% in the 2nd quarter. BNP Paribas Financial Markets now owns 6,889 shares of the company’s stock worth $64,000 after acquiring an additional 1,879 shares during the period. Raymond James Financial Inc. acquired a new stake in Replimune Group in the second quarter valued at approximately $69,000. Finally, Russell Investments Group Ltd. raised its stake in shares of Replimune Group by 3,638.9% during the third quarter. Russell Investments Group Ltd. now owns 7,777 shares of the company’s stock valued at $33,000 after purchasing an additional 7,569 shares during the period. 92.53% of the stock is owned by hedge funds and other institutional investors.

Replimune Group Company Profile

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.